Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin

Jessica Fraeyman1 Department of Epidemiology and Social Medicine, Research Unit of Medical Sociology and Health Policy,University of Antwerp,Antwerp,2610,Belgium.Correspondence[email protected]

Hans De Loof2 Division of Physiopharmacology,University of Antwerp,Antwerp,2610,Belgium.

Guido Van Hal1 Department of Epidemiology and Social Medicine, Research Unit of Medical Sociology and Health Policy,University of Antwerp,Antwerp,2610,Belgium.

Guido De Meyer2 Division of Physiopharmacology,University of Antwerp,Antwerp,2610,Belgium.

Roy Remmen3 Department of Primary and Interdisciplinary Care,University of Antwerp,Antwerp,2610,Belgium.

Philippe Beutels4 Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID),Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp,Antwerp,2610,Belgium.;5 School of Public Health and Community Medicine,The University of New South Wales,Sydney,Australia.

Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin

Reference

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin

Reference

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date